دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
ESTRO ACROP guidelines for target volume definition in pancreatic cancer
Thomas B. Brunner, Karin Haustermans, Florence Huguet, Alessio G. Morganti, ... Falk Roeder
doi : 10.1016/j.radonc.2020.07.052
Volume 154, January 2021, Pages 60-69
Despite of the predominant role of chemotherapy and surgery in pancreatic ductal adenocarcinoma (PDAC), radiotherapy (RT) still has a place in multimodal management of this disease where local tumour sequelae are fatal in about 40% of the patients. RT (chemoradiotherapy and stereotactic body radiotherapy) is used and investigated in the non-metastatic setting as part of definitive treatment strategies, in (neo)adjuvant settings and for locally recurrent disease.
NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer
Huakang Huang, John Roberson, Wei Hou, Kartik Mani, ... Alexander Stessin
doi : 10.1016/j.radonc.2020.09.003
Volume 154, January 2021, Pages 87-92
Hypothyroidism (HT) is a well-known complication of radiation (RT) that includes supraclavicular (SCV) fields. We analyzed breast cancer patients who received SCV-directed RT to evaluate predictors of HT and developed the first normal tissue complication probability (NTCP) model for HT specific to breast cancer patients.
Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study?
Kurian Joseph, Sarah Zebak, Veronica Alba, Kayla Mah, ... Karen King
doi : 10.1016/j.radonc.2020.09.017
Volume 154, January 2021, Pages 93-100
The relative benefit of adjuvant radiotherapy (RT) alone in older women with low-risk early breast cancer (EBC) remains unclear. It is hypothesized that adjuvant RT-alone can improve outcomes of older patients with low-risk EBC, similar to endocrine therapy (ET) alone or combination of RT + ET.
Dose-sparing effect of deep inspiration breath hold technique on coronary artery and left ventricle segments in treatment of breast cancer?
Jiheon Song, Terence Tang, Jean-Michel Caudrelier, Jason Bélec, ... Vimoj Nair
doi : 10.1016/j.radonc.2020.09.019
Volume 154, January 2021, Pages 101-109
The risk of radiation-induced cardiac injury remains a challenging problem in the treatment of breast cancer. Certain cardiac structures receive higher doses than others, which results in variable frequencies of radiation-induced injuries across these structures. Radiation dose can be reduced using the deep inspiration breath hold (DIBH) technique. We aimed to investigate the dose reductions from DIBH in individual cardiac segments.
Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03
Kyu Hye Choi, Sung Ja Ahn, Jae Uk Jeong, Mina Yu, ... Jong Hoon Lee
doi : 10.1016/j.radonc.2020.09.043
Volume 154, January 2021, Pages 179-186
To investigate the safety and efficacy of intensity-modulated radiation therapy (IMRT) for early breast cancer compared with 3-dimensional conformal radiotherapy (3D-CRT) in a prospective and randomized trial.
Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma
J. Biau, E. Thivat, E. Chautard, D. Stefan, ... X. Durando
doi : 10.1016/j.radonc.2020.09.036
Volume 154, January 2021, Pages 227-234
This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients.
Significant correlation between gross tumor volume (GTV) D98% and local control in multifraction stereotactic radiotherapy (MF-SRT) for unresected brain metastases
Guillaume Dupic, Lucie Brun, Ioana Molnar, Brice Leyrat, ... Julian Biau
doi : 10.1016/j.radonc.2020.11.021
Volume 154, January 2021, Pages 260-268
Stereotactic radiotherapy (SRT) should be applied with a biologically effective dose with an ?/? of 12 (BED12) ? 40 Gy to reach a 1-year local control (LC) ? 70%. The aims of this retrospective study were to report a series of 81 unresected large brain metastases treated with Linac-based multifraction SRT according to the ICRU 91 and to identify predictive factors associated with LC.
Proton therapy for selected low grade glioma patients in the Netherlands
Hiska L. van der Weide, Miranda C.A. Kramer, Daniel Scandurra, Daniëlle B.P. Eekers, ... Johannes A. Langendijk
doi : 10.1016/j.radonc.2020.11.004
Volume 154, January 2021, Pages 283-290
Proton therapy offers an attractive alternative to conventional photon-based radiotherapy in low grade glioma patients, delivering radiotherapy with equivalent efficacy to the tumour with less radiation exposure to the brain. In the Netherlands, patients with favourable prognosis based on tumour and patient characteristics can be offered proton therapy. Radiation-induced neurocognitive function decline is a major concern in these long surviving patients.
Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma
Yihuai Hu, Chenyi Xie, Hong Yang, Joshua W.K. Ho, ... Jianhua Fu
doi : 10.1016/j.radonc.2020.09.014
Volume 154, January 2021, Pages 6-13
Deep learning is promising to predict treatment response. We aimed to evaluate and validate the predictive performance of the CT-based model using deep learning features for predicting pathologic complete response to neoadjuvant chemoradiotherapy (nCRT) in esophageal squamous cell carcinoma (ESCC).
Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials
Maria Antonietta Gambacorta, Carlotta Masciocchi, Giuditta Chiloiro, Elisa Meldolesi, ... Vincenzo Valentini
doi : 10.1016/j.radonc.2020.09.026
Volume 154, January 2021, Pages 154-160
Optimal timing of surgery after neoadjuvant chemoradiotherapy (Nad-CRT) is still controversial in locally advanced rectal cancer (LARC). The primary goal of this study was to determine the best surgical interval (SI) to achieve the highest rate of pathological complete response (pCR) and secondly to evaluate the effect on survival outcomes according to the SI.
Prognostic value of multiparametric MRI-based radiomics model: Potential role for chemotherapeutic benefits in locally advanced rectal cancer
Yanfen Cui, Wenhui Yang, Jialiang Ren, Dandan Li, ... Xiaotang Yang
doi : 10.1016/j.radonc.2020.09.039
Volume 154, January 2021, Pages 161-169
We aimed to develop a radiomics model for the prediction of survival and chemotherapeutic benefits using pretreatment multiparameter MR images and clinicopathological features in patients with locally advanced rectal cancer (LARC).
Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience
M.P.W. Intven, S.R. de Mol van Otterloo, S. Mook, P.A.H. Doornaert, ... R.H.N. Tijssen
doi : 10.1016/j.radonc.2020.09.024
Volume 154, January 2021, Pages 172-178
Daily online adaptation of the clinical target volume (CTV) using MR-guided radiotherapy enables margin reduction of the planning target volume (PTV). This study describes the implementation and initial experience of MR-guided radiotherapy on the 1.5T MR-linac and evaluates treatment time, patient compliance, and target coverage, including an initial assessment of margin reduction.
Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer
Jie Li, Yixue Wen, Zhongzheng Xiang, Huan Du, ... Xiaobo Du
doi : 10.1016/j.radonc.2020.09.042
Volume 154, January 2021, Pages 201-206
This study aimed to evaluate the efficacy of radical radiotherapy and assess prognostic factors in metachronous oligometastatic esophageal cancer (MOEC) patients after initial treatment with curative-intent surgery and/or chemoradiotherapy.
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost
Yasir Alayed, Andrew Loblaw, Merrylee McGuffin, Hans T. Chung, ... Gerard Morton
doi : 10.1016/j.radonc.2020.09.007
Volume 154, January 2021, Pages 29-35
Single-fraction HDR monotherapy for the treatment of localized prostate cancer is appealing, but published outcomes are discouraging. An approach to improve local control is MRI-guided focal dose-escalation to the dominant intraprostatic lesion (DIL). Here we report a comparison of outcomes from two phase II clinical trials with and without a focal boost.
Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis
Lucas C. Mendez, Andrew Loblaw, Hans T. Chung, Chia-Lin Tseng, ... Gerard Morton
doi : 10.1016/j.radonc.2020.09.023
Volume 154, January 2021, Pages 118-122
To determine factors associated with need for post-procedural catheterization in prostate cancer patients treated with 15 Gy high dose-rate brachytherapy boost (HDR-BT).
Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control
Rebecca G. Levin-Epstein, Naomi Y. Jiang, Xiaoyan Wang, Shrinivasa K. Upadhyaya, ... Amar U. Kishan
doi : 10.1016/j.radonc.2020.09.053
Volume 154, January 2021, Pages 207-213
The optimal dose for prostate stereotactic body radiotherapy (SBRT) is still unknown. This study evaluated the dose–response relationships for prostate-specific antigen (PSA) decay and biochemical recurrence (BCR) among 4 SBRT dose regimens.
Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results
Peter J. Hoskin, Ana M. Rojas, Peter J. Ostler, Linda Bryant, Gerry J. Lowe
doi : 10.1016/j.radonc.2020.09.047
Volume 154, January 2021, Pages 214-219
A randomised phase-III trial compared external beam radiotherapy (EBRT) alone with EBRT combined with high-dose-rate brachytherapy boost (HDR-BTb) in localised prostate adenocarcinoma. Previous analysis, at median follow up of 85 months, demonstrated improved relapse free survival (RFS) with EBRT + HDR-BTb. This data has now been updated with a median follow up of 131 months.
Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer
Detlef Bartkowiak, Reinhard Thamm, Alessandra Siegmann, Dirk B?hmer, ... Thomas Wiegel
doi : 10.1016/j.radonc.2020.09.009
Volume 154, January 2021, Pages 255-259
In prostate cancer (PCa) recurring after radical prostatectomy (RP), salvage radiotherapy (SRT) is recommended to be given at PSA <0.5 ng/ml. It has been speculated, that the advantage from early SRT is mainly caused by lead-time bias: Calculating from time of SRT, earlier treatment would per-se result in longer time to event/censoring compared with later treatment, but not extend the interval from RP to post-SRT failure.
Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach
Ali Hosni, Kevin Chiu, Shao Hui Huang, Wei Xu, ... Andrew Hope
doi : 10.1016/j.radonc.2020.08.013
Volume 154, January 2021, Pages 70-75
To determine the outcomes of oral cavity squamous cell cancer (OSCC) patients treated with non-surgical approach i.e. definitive intensity-modulated radiation therapy (IMRT).
Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study
Chia-Hsin Lin, Wen-Chi Chou, Yao-Yu Wu, Chien-Yu Lin, ... Ngan-Ming Tsang
doi : 10.1016/j.radonc.2020.09.012
Volume 154, January 2021, Pages 76-86
We sought to investigate whether dynamic changes in lymphocyte-to-monocyte ratio (LMR) occurring during the course of radiotherapy (RT) may have prognostic value in patients with head and neck cancer (HNC).
Dose volume histogram constraints in patients with head and neck cancer treated with surgery and adjuvant HDR brachytherapy: A proposal of the head and neck and skin GEC ESTRO Working group
Alejandro Garc?a-Consuegra, Marta Gimeno Morales, Mauricio Cambeiro, Luca Tagliaferri, ... Rafael Martinez-Monge
doi : 10.1016/j.radonc.2020.09.015
Volume 154, January 2021, Pages 128-134
The Head and Neck and Skin (HNS) Working group of the GEC-ESTRO acknowledges the lack of widely accepted Dose Volume Histogram (DVH) constraints in adjuvant head and neck brachytherapy and issues recommendations to minimize mandibular Osteoradionecrosis (ORN) and Soft Tissue Necrosis (STN).
Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation
Alexander Rühle, Carmen Stromberger, Erik Haehl, Carolin Senger, ... Nils H. Nicolay
doi : 10.1016/j.radonc.2020.11.023
Volume 154, January 2021, Pages 276-282
To establish a clinically feasible prognostic score and nomogram based on easily accessible clinical data that will aid decision-making in elderly head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy.
Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine
Markus Glatzer, Corinne Faivre-Finn, Dirk De Ruysscher, Joachim Widder, ... Paul M. Putora
doi : 10.1016/j.radonc.2020.10.043
Volume 154, January 2021, Pages 269-273
Whole brain radiotherapy (WBRT) is a common treatment option for brain metastases secondary to non-small cell lung cancer (NSCLC). Data from the QUARTZ trial suggest that WBRT can be omitted in selected patients and treated with optimal supportive care alone. Nevertheless, WBRT is still widely used to treat brain metastases secondary to NSCLC. We analysed decision criteria influencing the selection for WBRT among European radiation oncology experts.
Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor
Melanie A. Morrison, Sabine Mueller, Erin Felton, Angela Jakary, ... Janine M. Lupo
doi : 10.1016/j.radonc.2020.09.028
Volume 154, January 2021, Pages 145-153
Radiation therapy (RT) is essential to the management of many brain tumors, but has been known to lead to cognitive decline and vascular injury in the form of cerebral microbleeds (CMBs).
The radiotherapy utilization rate in pediatric tumors: An analysis of 13,305 patients
Mai K. Bishr, Mohamed S. Zaghloul, Caroline Elmaraghi, Ahmed Galal, ... Amr G. Mousa
doi : 10.1016/j.radonc.2020.09.058
Volume 154, January 2021, Pages 220-226
Although the radiotherapy utilization rate (RUR) is determined for most adult cancers, it is seldom reported in childhood tumors, particularly in low- and middle-income countries (LMIC) where the majority of pediatric cancer patients reside. This study aims to investigate the real-life RUR for pediatric tumors in a large LMIC center.
Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan
Yusuke Demizu, Reiko Imai, Hiroki Kiyohara, Akira Matsunobu, ... Tadashi Kamada
doi : 10.1016/j.radonc.2020.09.018
Volume 154, January 2021, Pages 1-5
Usefulness of carbon ion radiotherapy (CIRT) for sacral chordoma has been reported from single institutions. We conducted a retrospective nationwide multicentre study to evaluate the clinical outcomes of CIRT for sacral chordoma in Japan.
Clinical implementation of 3D in vivo dosimetry for abdominal and pelvic stereotactic treatments
Marco Esposito, Alessandro Ghirelli, Silvia Pini, Paolo Alpi, ... Serenella Russo
doi : 10.1016/j.radonc.2020.09.011
Volume 154, January 2021, Pages 14-20
To analyze results from three years of in vivo transit EPID dosimetry of abdominal and pelvic stereotactic radiotherapy and to establish tolerance levels for routine clinical use.
Head and neck IMPT probabilistic dose accumulation: Feasibility of a 2 mm setup uncertainty setting
Dirk Wagenaar, Roel G.J. Kierkels, Arjen van der Schaaf, Arturs Meijers, ... Stefan Both
doi : 10.1016/j.radonc.2020.09.001
Volume 154, January 2021, Pages 45-52
To establish optimal robust optimization uncertainty settings for clinical head and neck cancer (HNC) patients undergoing 3D image-guided pencil beam scanning (PBS) proton therapy.
Potential and pitfalls of 1.5T MRI imaging for target volume definition in ocular proton therapy
Riccardo Via, Fabian Hennings, Alessia Pica, Giovanni Fattori, ... Jan Hrbacek
doi : 10.1016/j.radonc.2020.08.023
Volume 154, January 2021, Pages 53-59
Ocular proton therapy (OPT) for the treatment of uveal melanoma has a long and remarkably successful history. This is despite that, for the majority of patients treated, the definition of the eye anatomy is based on a simplified geometrical model embedded in the treatment planning system EyePlan. In this study, differences in anatomical and tumor structures from EyePlan, and those based on 1.5T magnetic resonance imaging (MRI) are assessed.
Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases
Anita M. Werensteijn-Honingh, Ina M. Jürgenliemk-Schulz, Christa G. Gadellaa-Van Hooijdonk, Gonda G. Sikkes, ... Petra S. Kroon
doi : 10.1016/j.radonc.2020.09.021
Volume 154, January 2021, Pages 110-117
Vacuum cushion immobilization is commonly used during stereotactic body radiotherapy (SBRT) to reduce intrafraction motion. We investigated target and bony anatomy intrafraction motion (translations and rotations) during online adaptive SBRT on an MR-linac for pelvic/para-aortic lymph node metastases with and without vacuum cushion.
Clinical implementation of pencil beam scanning proton therapy for liver cancer with forced deep expiration breath hold
Francesco Fracchiolla, Francesco Dionisi, Roberto Righetto, Lamberto Widesott, ... Marco Schwarz
doi : 10.1016/j.radonc.2020.09.035
Volume 154, January 2021, Pages 137-144
To present our technique for liver cancer treatments with proton therapy in pencil beam scanning mode and to evaluate the impact of uncertainties on plan quality.
Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac
Dennis Winkel, Anita M. Werensteijn-Honingh, Wietse S.C. Eppinga, Martijn P.W. Intven, ... Petra S. Kroon
doi : 10.1016/j.radonc.2020.09.020
Volume 154, January 2021, Pages 243-248
At our department, MR-guided stereotactic body radiation therapy (SBRT) using the 1.5T MR-linac system (Unity, Elekta AB, Stockholm, Sweden) has been initiated for patients with lymph node oligometastases. Superior soft tissue contrast and the possibility for online plan adaptation on the Unity may allow for hypofractionated treatment. The purpose of this study was to investigate the dosimetric feasibility and compare the plan quality of different hypofractionated schemes.
Accuracy of dwell position detection with a combined electromagnetic tracking brachytherapy system for treatment verification in pelvic brachytherapy
Laura van Heerden, Jérémy Schiphof-Godart, Miranda Christianen, Jan-Willem Mens, ... Inger-Karine Kolkman-Deurloo
doi : 10.1016/j.radonc.2020.09.061
Volume 154, January 2021, Pages 249-254
To investigate the accuracy of dwell position detection with a combined electromagnetic tracking (EMT) brachytherapy (BT) system for treatment verification, by quantifying positional errors due to EM field interference in typical pelvic BT clinical settings.
High-throughput meta-analysis and validation of differentially expressed genes as potential biomarkers of ionizing radiation-response
Vanesa Biolatti, Lara Negrin, Nicol?s Bellora, Irene L. Iba?ez
doi : 10.1016/j.radonc.2020.09.010
Volume 154, January 2021, Pages 21-28
The high-throughput analysis of gene expression in ionizing radiation (IR)-exposed human peripheral white blood cells (WBC) has emerged as a novel method for biodosimetry markers detection. We aimed to detect IR-exposure differential expressed genes (DEGs) as potential predictive biomarkers for biodosimetry and radioinduced-response.
Integrating cullin2-RING E3 ligase as a potential biomarker for glioblastoma multiforme prognosis and radiosensitivity profiling
Shuhua Zheng, Yilin Wu, Zhenhao Li
doi : 10.1016/j.radonc.2020.09.005
Volume 154, January 2021, Pages 36-44
Positive epidermal growth factor receptor (EGFR) immunoreactivity in glioblastoma multiforme (GBM) often predicts poor radiation response. Meanwhile, all attempts to target EGFR pharmaceutically have been unsuccessful, mainly due to molecular heterogeneity of EGFR expression in GBM. A molecular biology-based and efficient way to access cellular protein levels of EGFR is urgently needed. EGFR, together with HIF-1? and Cyclin B1, is degraded via cullin2-RING E3 ligase (CRL2). It is worthwhile to investigate the possible involvement of CRL2 on GBM survival and radiosensitivity.
Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes
Xiaoxue Xie, Steven H. Lin, James W. Welsh, Xiong Wei, ... Ting Xu
doi : 10.1016/j.radonc.2020.09.002
Volume 154, January 2021, Pages 187-193
We investigated clinical and genetic factors associated with severe radiation-induced lymphopenia (RIL) in a randomized clinical trial of photon vs. proton radiation, with chemotherapy, for non-small cell lung cancer.
Inter/intra-tumoral dose response variations assessed using FDG-PET/CT feedback images: Impact on tumor control and treatment dose prescription
Di Yan, Shupeng Chen, Daniel J. Krauss, Rohan Deraniyagala, ... George Wilson
doi : 10.1016/j.radonc.2020.09.052
Volume 154, January 2021, Pages 235-242
To quantify inter/intra-tumoral variations of baseline metabolic activity and dose response. To evaluate their impact on tumor control and treatment dose prescription strategies.
Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer
Elske M. Gort, Jannet C. Beukema, Witold Matysiak, Nanna M. Sijtsema, ... Charlotte L. Brouwer
doi : 10.1016/j.radonc.2020.09.022
Volume 154, January 2021, Pages 194-200
Large-field photon radiotherapy is current standard in the treatment of cervical cancer patients. However, with the increasing availability of Pencil Beam Scanning Proton Therapy (PBS-PT) and robust treatment planning techniques, protons may have significant advantages for cervical cancer patients in the reduction of toxicity. In this study, PBS-PT and photon Volumetric Modulated Arc Therapy (VMAT) were compared, examining target coverage and organ at risk (OAR) dose, taking inter- and intra-fraction motion into account.
Can radiation-recall predict long lasting response to immune checkpoint inhibitors?
Eric Deutsch, Benjamin Besse, Jérôme Le Pavec, Cécile Le Péchoux, ... Antonin Levy
doi : 10.1016/j.radonc.2020.09.037
Volume 154, January 2021, Pages 125-127
Challenges influencing the utilization of prostate brachytherapy in the United States
Bismarck Odei, Sonu Bae, Dayssy Alexandra Diaz
doi : 10.1016/j.radonc.2020.09.025
Volume 154, January 2021, Pages 123-124
Letter to the editor concerning Offersen et al., [Radiother Oncol 2015; 114: 3–10]
Michael E.J. Stouthandel, Liv Veldeman, Tom Van Hoof
doi : 10.1016/j.radonc.2020.09.032
Volume 154, January 2021, Pages 135-136
In response to: “Intraoperative radiation therapy (IORT) for soft tissue sarcoma – ESTRO IORT task force/ACROP recommendations”
R.L. Haas, A. Gronchi
doi : 10.1016/j.radonc.2020.09.040
Volume 154, January 2021, Pages 170-171
Increased number of prostate cancer patients selecting high dose-rate interstitial brachytherapy during the COVID-19 pandemic
Naoya Murakami, Satoshi Nakamura, Tairo Kashihara, Koji Inaba, ... Jun Itami
doi : 10.1016/j.radonc.2020.11.015
Volume 154, January 2021, Pages 274-275
Corrigendum to “Interaction between CIEDs and modern radiotherapy techniques: Flattening filter free-VMAT, dose-rate effects, scatter radiation, and neutron-generating energies” [Radiother Oncol 152 (2020) 196–202]
Benjamin Gauter-Fleckenstein, Julia Nguyen, Lennart Jahnke, Timo Gaiser, ... Erol Tülümen
doi : 10.1016/j.radonc.2020.12.023
Volume 154, January 2021, Page 291
